Back to Search
Start Over
US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations.
- Source :
- EJNMMI Radiopharmacy & Chemistry; 5/22/2019, Vol. 4 Issue 1, pN.PAG-N.PAG, 1p
- Publication Year :
- 2019
-
Abstract
- New regulatory guidance documents from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recently been finalized or are in draft format outlining new pathways for preclinical safety testing. The US and the European Union appear to be moving in a similar direction focussing and refining preclinical safety data requirements for both radiodiagnostics and radiotherapeutics. We here summarize these recent documents from both the US and European perspective. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 2365421X
- Volume :
- 4
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- EJNMMI Radiopharmacy & Chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 136558545
- Full Text :
- https://doi.org/10.1186/s41181-019-0059-2